[G20-32] Ixekizumab (axial spondyloarthritis) - Addendum to Commission A20-66
Last updated 26.01.2021
Project no.:
G20-32
Commission:
Commission awarded on 22.12.2020 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Health Economics
Application field:
Muscles, bones and joints
Note:
If, in the course of the discussions on a commission of the G-BA, a need for further revision arises, IQWiG presents its report in the form of an addendum. The G-BA decides on the number of patients in the SHI target population.
| Project no. | Title | Status |
|---|---|---|
| A20-66 | Ixekizumab (spondylitis and spondyloarthritis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2021-01-26: A G-BA decision was published.